Get the Stockscreener App
1.3113
2.90%
-0.0487
Biomea Fusion Inc stock is traded at $1.3113, with a volume of 448.25K.
It is down -2.90% in the last 24 hours and down -38.58% over the past month.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
See More
Previous Close:
$1.36
Open:
$1.38
24h Volume:
448.25K
Relative Volume:
0.28
Market Cap:
$78.34M
Revenue:
-
Net Income/Loss:
$-144.01M
P/E Ratio:
-0.327
EPS:
-4.01
Net Cash Flow:
$-113.02M
1W Performance:
-7.01%
1M Performance:
-38.58%
6M Performance:
-39.43%
1Y Performance:
-85.39%
1-Day Range:
$1.30
$1.395
1-Week Range:
$1.30
$1.45
52-Week Range:
$1.2905
$9.34
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.3165 | 96.16M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.55 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.35 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.85 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.42 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
180.04 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-25 | Initiated | Jefferies | Buy |
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
Is Biomea Fusion Inc. stock trading at a premium valuationQuarterly Portfolio Summary & Weekly High Potential Alerts - newser.com
Is Biomea Fusion Inc. stock a dividend growth opportunity2025 Market Outlook & Safe Entry Momentum Stock Tips - newser.com
Can Biomea Fusion Inc. stock hit analyst price targetsWeekly Market Summary & Free Expert Verified Stock Movement Alerts - newser.com
Is Biomea Fusion Inc. stock dividend yield sustainable2025 Geopolitical Influence & Verified Momentum Stock Alerts - newser.com
Is Biomea Fusion Inc. a candidate for recovery playJuly 2025 Technicals & Real-Time Volume Analysis Alerts - newser.com
Strategies to average down on Biomea Fusion Inc.Fed Meeting & Daily Risk Controlled Trade Plans - newser.com
Is Biomea Fusion Inc. stock in correction or buying zonePortfolio Return Summary & Capital Protection Trade Alerts - newser.com
Biomea Fusion Inc.’s volatility index tracking explainedJuly 2025 Spike Watch & Free Reliable Trade Execution Plans - newser.com
Can trapped investors hope for a rebound in Biomea Fusion Inc.Portfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Can Biomea Fusion Inc. stock rebound after recent weaknessSell Signal & Daily Oversold Stock Bounce Ideas - newser.com
Is Biomea Fusion Inc. trending in predictive chart modelsJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Long term hold vs stop loss in Biomea Fusion Inc.2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Real time pattern detection on Biomea Fusion Inc. stock2025 EndofYear Setup & Weekly Market Pulse Alerts - newser.com
Biomea Fusion’s BMF-650: A New Hope in Obesity Treatment? - TipRanks
How risky is Biomea Fusion Inc. stock now2025 Trading Recap & Daily Profit Maximizing Tips - newser.com
Why Biomea Fusion Inc. stock could be next big winnerWeekly Loss Report & Daily Chart Pattern Signal Reports - newser.com
Biomea Fusion’s BMF-219 Trial for Type 1 Diabetes: A Terminated Phase 2 Study - TipRanks
Cormorant Asset Management, LP Reduces Stake in Biomea Fusion Inc - GuruFocus
Biomea Fusion stock hits 52-week low at $3.58 amid sharp decline - MSN
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025 - Investing News Network
Biomea Fusion, Inc. to Present Preclinical Data for BMF-650 and Icovamenib at ObesityWeek® 2025 - Quiver Quantitative
Biomea (Nasdaq: BMEA) to present ObesityWeek posters on BMF-650 and icovamenib/semaglutide - Stock Titan
Is Biomea Fusion Inc. stock bottoming outMarket Activity Summary & Capital Protection Trade Alerts - newser.com
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.85%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):